Prognosis and future developments in vasculitis

Basu, N. , Karabayas, M. and Pusey, C. (2018) Prognosis and future developments in vasculitis. Best Practice and Research: Clinical Rheumatology, 32(1), pp. 148-165. (doi:10.1016/j.berh.2018.08.011) (PMID:30526894)

Full text not currently available from Enlighten.

Abstract

The prognosis of ANCA-associated vasculitis has been transformed in recent years. Once it was a set of invariably acute and fatal conditions, but these disorders are currently considered to be chronic diseases. This change is largely attributable to earlier diagnosis and the careful application of immunotherapeutics. However, patients still experience premature mortality, relapse, comorbid ill health and poor quality of life. Mortality rates in large-vessel vasculitis are not comparable; however, morbidity and poor patient outcomes prevail. Toxicity secondary to glucocorticoids represents a common driver of poor outcomes across systemic vasculitis. The main thrust of future treatment strategies is to reduce if not eliminate exposure to these agents.

Item Type:Articles
Keywords:ANCA-associated vasculitis, giant cell arteritis, Takayasu arteritis.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Basu, Dr Neil
Authors: Basu, N., Karabayas, M., and Pusey, C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Best Practice and Research: Clinical Rheumatology
Publisher:Elsevier
ISSN:1521-6942
ISSN (Online):1532-1770
Published Online:22 September 2018

University Staff: Request a correction | Enlighten Editors: Update this record